Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACIU | US
-0.10
-2.87%
Healthcare
Biotechnology
30/06/2024
04/10/2024
3.38
3.43
3.50
3.32
AC Immune SA a clinical stage biopharmaceutical company discovers designs and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines antibodies and small molecules which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab a humanized conformation-specific monoclonal antibody which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24 an anti-Abeta vaccine candidate that is in Phase II clinical study for AD as well as completed Phase Ib clinical study for Down syndrome; ACI-35 an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer which is in Phase II clinical study. In addition the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases which include diagnostics targeting TDP-43 alpha-synuclein and NLRP3. AC Immune SA has license agreements and collaborations with Genentech Inc.; Biogen International GmbH; Janssen Pharmaceuticals Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne Switzerland.
View LessValue Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
41.0%1 month
45.6%3 months
59.1%6 months
87.2%-
11.36
2.56
-
-
-0.76
9.18
-
-58.44M
334.42M
334.42M
-
-3.05K
-
1.48M
-46.06
9.10
1.44
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.66
Range1M
1.06
Range3M
1.34
Rel. volume
0.72
Price X volume
243.44K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fate Therapeutics Inc | FATE | Biotechnology | 3.22 | 366.69M | 0.31% | n/a | 25.33% |
ITOS | ITOS | Biotechnology | 10.02 | 365.95M | 2.04% | n/a | 0.83% |
Corvus Pharmaceuticals Inc | CRVS | Biotechnology | 5.64 | 352.79M | 6.82% | n/a | 1.37% |
INZY | INZY | Biotechnology | 5.17 | 346.90M | 2.78% | n/a | 49.47% |
Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.71 | 339.86M | -0.73% | n/a | 13.86% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 6.49 | 337.66M | 2.69% | n/a | 0.38% |
XOMA Corporation | XOMA | Biotechnology | 27.64 | 323.51M | 0.95% | n/a | 121.93% |
MeiraGTx Holdings plc | MGTX | Biotechnology | 4.15 | 320.31M | -1.89% | n/a | 109.40% |
ADC Therapeutics SA | ADCT | Biotechnology | 3.29 | 318.10M | 8.22% | n/a | -94.48% |
Aldeyra Therapeutics Inc | ALDX | Biotechnology | 5.34 | 317.31M | 0.75% | n/a | 15.90% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.76 | 0.76 | Cheaper |
Ent. to Revenue | 9.18 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.56 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 59.14 | 74.67 | Lower Risk |
Debt to Equity | - | -1.82 | - |
Debt to Assets | - | 0.26 | - |
Market Cap | 334.42M | 3.73B | Emerging |